Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma

Objective Lymphocyte cytosolic protein 2 (LCP2) is often ectopically expressed in various human tumors. However, the clinical significance and role of LCP2 in lung adenocarcinoma (LUAD) remain unclear. This study explored the prognostic significance of LCP2 in LUAD patients. Methods LCP2 expression...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yishan Huo, Kainan Zhang, Songtao Han, Yangchun Feng, Yongxing Bao
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/aa5f3f99e38743f5b809e213ecae1d1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aa5f3f99e38743f5b809e213ecae1d1a
record_format	dspace
spelling	oai:doaj.org-article:aa5f3f99e38743f5b809e213ecae1d1a2021-12-02T03:04:02ZLymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma1473-230010.1177/03000605211059681https://doaj.org/article/aa5f3f99e38743f5b809e213ecae1d1a2021-11-01T00:00:00Zhttps://doi.org/10.1177/03000605211059681https://doaj.org/toc/1473-2300Objective Lymphocyte cytosolic protein 2 (LCP2) is often ectopically expressed in various human tumors. However, the clinical significance and role of LCP2 in lung adenocarcinoma (LUAD) remain unclear. This study explored the prognostic significance of LCP2 in LUAD patients. Methods LCP2 expression in LUAD tissues was analyzed using data from The Cancer Genome Atlas and Genotype-Tissue Expression databases. Western blotting was employed to detect LCP2 expression in LUAD. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to explore signaling pathways mediated by LCP2 co-regulatory genes. Immunohistochemistry was used to examine levels of LCP2 and programmed death ligand 1 (PD-L1) in 68 LUAD patients. Associations between LCP2 expression and clinicopathological features, prognoses, and PD-L1 levels among the LUAD in-patients were analyzed. Results Among the 68 LUAD in-patients, LCP2 expression was correlated with clinical stage and lymph node metastasis. LUAD patients with high LCP2 expression were associated with increased overall survival. LCP2 expression may be associated with an enrichment of several immune functions. Moreover, our immunohistochemistry results demonstrated that LCP2 expression was positively correlated with PD-L1 expression in LUAD tissues. Conclusions In the study, LCP2 was found to be a favorable prognostic biomarker in LUAD patients.Yishan HuoKainan ZhangSongtao HanYangchun FengYongxing BaoSAGE PublishingarticleMedicine (General)R5-920ENJournal of International Medical Research, Vol 49 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Yishan Huo Kainan Zhang Songtao Han Yangchun Feng Yongxing Bao Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma
description	Objective Lymphocyte cytosolic protein 2 (LCP2) is often ectopically expressed in various human tumors. However, the clinical significance and role of LCP2 in lung adenocarcinoma (LUAD) remain unclear. This study explored the prognostic significance of LCP2 in LUAD patients. Methods LCP2 expression in LUAD tissues was analyzed using data from The Cancer Genome Atlas and Genotype-Tissue Expression databases. Western blotting was employed to detect LCP2 expression in LUAD. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to explore signaling pathways mediated by LCP2 co-regulatory genes. Immunohistochemistry was used to examine levels of LCP2 and programmed death ligand 1 (PD-L1) in 68 LUAD patients. Associations between LCP2 expression and clinicopathological features, prognoses, and PD-L1 levels among the LUAD in-patients were analyzed. Results Among the 68 LUAD in-patients, LCP2 expression was correlated with clinical stage and lymph node metastasis. LUAD patients with high LCP2 expression were associated with increased overall survival. LCP2 expression may be associated with an enrichment of several immune functions. Moreover, our immunohistochemistry results demonstrated that LCP2 expression was positively correlated with PD-L1 expression in LUAD tissues. Conclusions In the study, LCP2 was found to be a favorable prognostic biomarker in LUAD patients.
format	article
author	Yishan Huo Kainan Zhang Songtao Han Yangchun Feng Yongxing Bao
author_facet	Yishan Huo Kainan Zhang Songtao Han Yangchun Feng Yongxing Bao
author_sort	Yishan Huo
title	Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma
title_short	Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma
title_full	Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma
title_fullStr	Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma
title_full_unstemmed	Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma
title_sort	lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/aa5f3f99e38743f5b809e213ecae1d1a
work_keys_str_mv	AT yishanhuo lymphocytecytosolicprotein2isanovelprognosticmarkerinlungadenocarcinoma AT kainanzhang lymphocytecytosolicprotein2isanovelprognosticmarkerinlungadenocarcinoma AT songtaohan lymphocytecytosolicprotein2isanovelprognosticmarkerinlungadenocarcinoma AT yangchunfeng lymphocytecytosolicprotein2isanovelprognosticmarkerinlungadenocarcinoma AT yongxingbao lymphocytecytosolicprotein2isanovelprognosticmarkerinlungadenocarcinoma
_version_	1718402001594744832

Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma

Ejemplares similares